Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Travel-related acquisition of diarrhoeagenic bacteria, enteral viruses and parasites in a prospective cohort of 98 Dutch travellers.

van Hattem JM, Arcilla MS, Grobusch MP, Bart A, Bootsma MC, van Genderen PJ, van Gool T, Goorhuis A, van Hellemond JJ, Molenkamp R, Molhoek N, Oude Lashof AM, Stobberingh EE, de Wever B, Verbrugh HA, Melles DC, Penders J, Schultsz C, de Jong MD.

Travel Med Infect Dis. 2017 Aug 24. pii: S1477-8939(17)30125-4. doi: 10.1016/j.tmaid.2017.08.003. [Epub ahead of print]

PMID:
28842214
2.

Detection of the plasmid-mediated colistin-resistance gene mcr-1 in faecal metagenomes of Dutch travellers.

von Wintersdorff CJ, Wolffs PF, van Niekerk JM, Beuken E, van Alphen LB, Stobberingh EE, Oude Lashof AM, Hoebe CJ, Savelkoul PH, Penders J.

J Antimicrob Chemother. 2016 Dec;71(12):3416-3419. Epub 2016 Aug 23.

PMID:
27559117
3.

Prolonged carriage and potential onward transmission of carbapenemase-producing Enterobacteriaceae in Dutch travelers.

van Hattem JM, Arcilla MS, Bootsma MC, van Genderen PJ, Goorhuis A, Grobusch MP, Molhoek N, Oude Lashof AM, Schultsz C, Stobberingh EE, Verbrugh HA, de Jong MD, Melles DC, Penders J.

Future Microbiol. 2016 Jul;11:857-64. doi: 10.2217/fmb.16.18. Epub 2016 Jun 30.

4.

Diagnosis and management of aspergillosis in the Netherlands: a national survey.

Lestrade PP, Meis JF, Arends JP, van der Beek MT, de Brauwer E, van Dijk K, de Greeff SC, Haas PJ, Hodiamont CJ, Kuijper EJ, Leenstra T, Muller AE, Oude Lashof AM, Rijnders BJ, Roelofsen E, Rozemeijer W, Tersmette M, Terveer EM, Verduin CM, Wolfhagen MJ, Melchers WJ, Verweij PE.

Mycoses. 2016 Feb;59(2):101-7. doi: 10.1111/myc.12440. Epub 2015 Dec 9.

PMID:
26648179
5.

Risk stratification by abbMEDS and CURB-65 in relation to treatment and clinical disposition of the septic patient at the emergency department: a cohort study.

Roest AA, Tegtmeier J, Heyligen JJ, Duijst J, Peeters A, Borggreve HF, Oude Lashof AM, Stehouwer CD, Stassen PM.

BMC Emerg Med. 2015 Oct 13;15:29. doi: 10.1186/s12873-015-0056-z.

6.

High rates of antimicrobial drug resistance gene acquisition after international travel, The Netherlands.

von Wintersdorff CJ, Penders J, Stobberingh EE, Oude Lashof AM, Hoebe CJ, Savelkoul PH, Wolffs PF.

Emerg Infect Dis. 2014 Apr;20(4):649-57. doi: 10.3201/eid.2004.131718.

7.

Does a patient-level quantitative review of randomized trials on the outcomes in candidemia and invasive candidiasis need to include all patients?

Oude Lashof AM, Vogelaers D.

Clin Infect Dis. 2013 May;56(10):1514-5. doi: 10.1093/cid/cit061. Epub 2013 Feb 5. No abstract available.

PMID:
23386635
8.

Temporary antiretroviral treatment during primary HIV-1 infection has a positive impact on health-related quality of life: data from the Primo-SHM cohort study.

Grijsen M, Koster G, van Vonderen M, van Kasteren M, Kootstra G, Steingrover R, de Wolf F, Prins J, Nieuwkerk P; Primo-SHM study group.

HIV Med. 2012 Nov;13(10):630-5. doi: 10.1111/j.1468-1293.2012.01020.x. Epub 2012 Apr 25.

9.

No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.

Grijsen ML, Steingrover R, Wit FW, Jurriaans S, Verbon A, Brinkman K, van der Ende ME, Soetekouw R, de Wolf F, Lange JM, Schuitemaker H, Prins JM; Primo-SHM Study Group.

PLoS Med. 2012;9(3):e1001196. doi: 10.1371/journal.pmed.1001196. Epub 2012 Mar 27.

10.

Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia.

Oude Lashof AM, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, Rex JH, Kullberg BJ.

Antimicrob Agents Chemother. 2012 Jun;56(6):3133-7. doi: 10.1128/AAC.05841-11. Epub 2012 Mar 26.

11.

The first locally acquired human infection of Echinococcus multilocularis in The Netherlands.

van Dommelen L, Stoot JH, Cappendijk VC, Abdul Hamid MA, Stelma FF, Kortbeek LM, van der Giessen J, Oude Lashof AM.

J Clin Microbiol. 2012 May;50(5):1818-20. doi: 10.1128/JCM.06355-11. Epub 2012 Feb 22.

12.

Ocular manifestations of candidemia.

Oude Lashof AM, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, Oborska IT, Rex JH, Kullberg BJ.

Clin Infect Dis. 2011 Aug 1;53(3):262-8. doi: 10.1093/cid/cir355.

PMID:
21765074
13.

Q fever (Coxiella burnetii) causing an infected thoracoabdominal aortic aneurysm.

Bendermacher BL, Peppelenbosch AG, Daemen JW, Oude Lashof AM, Jacobs MJ.

J Vasc Surg. 2011 May;53(5):1402-4. doi: 10.1016/j.jvs.2010.11.102. Epub 2011 Jan 26.

14.

Design of efficacy trials of cytokines in combination with antifungal drugs.

Kullberg BJ, Oude Lashof AM, Netea MG.

Clin Infect Dis. 2004 Oct 15;39 Suppl 4:S218-23.

PMID:
15546121
15.

[Amphotericin B: the end of an era].

Oude Lashof AM, Kullberg BJ.

Ned Tijdschr Geneeskd. 2004 Aug 21;148(34):1665-8. Dutch. Erratum in: Ned Tijdschr Geneeskd. 2004 Oct 2;148(40):2004.

PMID:
15453116
16.

An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis.

Oude Lashof AM, De Bock R, Herbrecht R, de Pauw BE, Krcmery V, Aoun M, Akova M, Cohen J, Siffnerov√° H, Egyed M, Ellis M, Marinus A, Sylvester R, Kullberg BJ; EORTC Invasive Fungal Infections Group.

Eur J Cancer. 2004 Jun;40(9):1314-9.

PMID:
15177489
17.

Voriconazole salvage treatment of invasive candidiasis.

Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH.

Eur J Clin Microbiol Infect Dis. 2003 Nov;22(11):651-5. Epub 2003 Oct 17.

PMID:
14564539
18.

Duration of antifungal treatment and development of delayed complications in patients with candidaemia.

Oude Lashof AM, Donnelly JP, Meis JF, van der Meer JW, Kullberg BJ.

Eur J Clin Microbiol Infect Dis. 2003 Jan;22(1):43-8. Epub 2003 Jan 25.

PMID:
12582743
19.

Epidemiology of opportunistic invasive mycoses.

Kullberg BJ, Oude Lashof AM.

Eur J Med Res. 2002 May 31;7(5):183-91. Review.

PMID:
12069910

Supplemental Content

Loading ...
Support Center